Related Experiment Video
Updated: Aug 16, 2026

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
Published on: August 17, 2010
Iloperidone (Hoechst Marion Roussel Inc)
1abfab@jmulder.demon.nl
Abstract:
Iloperidone (HP-873) is a 5-HT2 antagonist from Hoechst Marion Roussel Inc in clinical trials for the treatment of schizophrenia and psychosis. In May 1996, the company announced that it had discontinued further development of the compound. This announcement, however, was followed in January 1997 by the news that Hoechst had licensed the compound to Titan Pharmaceuticals, on a worldwide exclusive basis. Subsequently, Titan granted Novartis worldwide development, manufacturing and marketing rights, excluding Japan. In August 1998, Novartis commenced phase III trials for iloperidone to treat schizophrenia. The trial will include 3000 patients in 20 countries. In receptor binding assays it has moderate affinity for the D2 receptor and greater affinity for the 5-HT2 receptor. This is thought to be an important factor for atypical antipsychotic activity and reduction of extrapyramidal side-effects.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Opioid Receptors: Overview
